APC/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, ? APC/Cyanine7 isotype control (right).
  • 53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, ? APC/Cyanine7 isotype control (right).
See APC/Cyanine7 spectral data
Cat # Size Price Quantity Avail. Save
100713 25 µg 68€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100714 100 µg 156€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, and immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
Product Citations
  1. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  2. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  3. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  4. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
  5. Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed
  6. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  7. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  8. Lian G et al. 2018. eLife. 7 pii: e36158. PubMed
  9. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  10. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  11. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  12. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  13. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  14. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  15. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  16. Das S, et al. 2019. Oncogene. 383316. PubMed
  17. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  18. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  19. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  20. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  21. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  22. Fu Z, et al. 2019. Cell Rep. 28:159. PubMed
  23. Wei SC, et al. 2019. Immunity. 50:1084. PubMed
  24. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  25. Miragaia RJ, et al. 2019. Immunity. 50:493. PubMed
  26. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
  27. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  28. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  29. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  30. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  31. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  32. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  33. Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
  34. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  35. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  36. Martin MD, et al. 2020. Cell Rep. 31:107508. PubMed
  37. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
  38. Guo X, et al. 2020. Nat Commun. 11:2177. PubMed
  39. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  40. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  41. Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed
  42. Flosbach M, et al. 2020. Cell Reports. 32(4):107957. PubMed
  43. Chew HY, et al. 2020. Cell. 180(5):895-914. PubMed
  44. Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed
  45. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  46. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  47. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  48. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  49. Chen J, et al. 2008. Blood. 111:5163. PubMed
  50. Shoji M, et al. 2012. PLoS One. 7:e30302. PubMed
  51. Kastenmüller K, et al. 2013. Infect Immun . 81:789. PubMed
  52. Spranger S, et al. 2013. Sci Transl Med. 26:200. PubMed
  53. Quinn K, et al. 2013. J Immunol. 191:5085. PubMed
  54. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  55. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  56. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  57. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  58. Gough D, et al. 2014. Blood. 124:2252. PubMed
  59. Singhal A, et al. 2014. Sci Transl Med. 6:263. PubMed
  60. Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed
  61. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  62. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  63. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  64. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  65. Cabrera-Mora M, et al. 2016. J Immunol. 197: 2748 - 2761. PubMed
  66. Zhou Y, et al. 2016. Acta Pharmacol Sin. 10.1038/aps.2016.102. PubMed
  67. Hirako I, et al. 2016. Nat Commun. 7:13277. PubMed
  68. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  69. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  70. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  71. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  72. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  73. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  74. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  75. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  76. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  77. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  78. Lynn GM, et al. 2020. Nat Biotechnol. 38:320. PubMed
  79. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  80. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  81. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  82. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  83. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  84. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  85. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  86. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  87. Marangoni F, et al. 2021. Cell. . PubMed
  88. Giampazolias E, et al. 2021. Cell. . PubMed
RRID
AB_312752 (BioLegend Cat. No. 100713)
AB_312753 (BioLegend Cat. No. 100714)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 01.30.2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account